OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
January 02, 2009
Catalysis for olefin metathesis and aldol reactions and synthetic routes to natural products are some recent gains.
The authors examine the challenges of integrating a large-scale chromatography and nanofiltration process for purification of a polyclonal antibody.
Although its domestic market is on the rise, Pakistan's market conditions have not proved welcoming enough to keep foreign investors.
The financial crisis could lead to consolidation in the contract services industry.
In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations
From The Editor
The incoming administration has renewed hope for stem cells, but less adequate copycats may follow.
After a year of increased attention on the pharmaceutical supply chain in Asia, what will be the region's short- and long-term role? This article contains bonus online-exclusive material.
The authors propose that a postapproval management plan can serve as a tool to apply science- and risk-based approaches to the manufacturing process.
A book explains the many pharmaceutical applications of polymers from natural sources.
Brief pharmaceutical news items for January 2009.
The authors describe a novel analytical approach that uses the shape-analysis capabilities of MFI to detect and enumerate silicone oil microdroplets in protein formulations that also contain aggregates of similar size and in a similar concentration.
The USP public-comment process exists for a reason. Industry needs to take advantage. This article contains bonus online-exclusive material.
Will more resources and new leadership fix FDA, or is a major overhaul in order?
The authors propose an approach for qualification-target selection and show how it can be applied to blister-filling and packaging systems.
Instead of hampering progress, cost pressures might inspire Big Pharma to get creative.
President Obama's choice for agency leadership should take into account several factors.
Readers give advice on their best approach to handling (batch) rejection